How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics, Inc. (NASDAQ:NVUS) announced its quarterly earnings data on Monday, November, 16th. The biopharmaceutical company reported ($5.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.64) by $3.87. Read the conference call transcript .

When did Novus Therapeutics' stock split?

Novus Therapeutics's stock reverse split on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Novus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , SCYNEXIS (SCYX) , CymaBay Therapeutics (CBAY) , Novavax (NVAX) , Geron (GERN) , Inovio Pharmaceuticals (INO) , Verastem (VSTM) and vTv Therapeutics (VTVT) .

NASDAQ:NVUS

Novus Therapeutics (NVUS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free NVUS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.55
▼
$1.68
50-Day Range: $9.85
▼
$16.50
52-Week Range: $4.50
▼
$27.32

Volume: 12,526 shs
Average Volume: 78,851 shs
Market Capitalization: $2.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Novus Therapeutics alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Novus Therapeutics Stock (NASDAQ:NVUS)

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

NVUS Stock News Headlines

March 1, 2024 | morningstar.com

Vivoryon Therapeutics NV VVY

February 22, 2024 | money.usnews.com

Viking Therapeutics Inc

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

December 28, 2023 | seekingalpha.com

CYT Cyteir Therapeutics, Inc.

May 11, 2023 | finance.yahoo.com

Novo Holdings invests in US$105 million Series C Funding of Alentis Therapeutics

March 31, 2023 | benzinga.com

ProQR Therapeutics Stock (NASDAQ:PRQR), Analyst Ratings, Price Targets, Predictions

March 30, 2023 | finance.yahoo.com

Sales Revenue from CNS Therapeutics Market to Top US$ 142.1 Billion by 2026: Fact.MR Analysis

March 29, 2023 | proactiveinvestors.com

Chimeric Therapeutics welcomes “positive” feedback following pre-IND meeting with US FDA for Phase 1 CAR-T study

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 25, 2023 | usnews.com

East Career Technical Academy

March 25, 2023 | usnews.com

Las Vegas Academy of the Arts

February 22, 2023 | money.usnews.com

Perspective Therapeutics Inc

February 12, 2023 | finance.yahoo.com

Onychomycosis Therapeutics Market Size Worth US$ ~8,420.3 million , Globally, by 2030 at 6% CAGR

See More Headlines

Receive NVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/16/2020
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NVUS
CUSIP: N/A
CIK: 1404281
Web: novustherapeutics.com
Phone: 949-238-8090
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($21.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,010,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -133.49%
Return on Assets: -30.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.78
Quick Ratio: 18.78

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $13.13 per share
Price / Book: 0.12

Miscellaneous

Outstanding Shares: 1,436,000
Free Float: N/A
Market Cap: $2.25 million
Optionable: Not Optionable
Beta: 2.07

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Jon S. Kuwahara CPA (Age 55)
CPA, SVP of Fin. & Admin., Principal Financial Officer and Principal Accounting Officer
Comp: $295.72k
Mr. Gregory J. Flesher (Age 50)
Consultant
Comp: $482.13k
Dr. David-Alexandre C. Gros M.D. (Age 48)
CEO & Non Independent Director
Dr. Steven N. Perrin Ph.D. (Age 55)
Pres, Chief Scientific Officer & Non Independent Director

Key Competitors

View All Competitors

NVUS Stock Analysis - Frequently Asked Questions

How were Novus Therapeutics' earnings last quarter?: Novus Therapeutics, Inc. (NASDAQ:NVUS) announced its quarterly earnings data on Monday, November, 16th. The biopharmaceutical company reported ($5.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.64) by $3.87.
Read the conference call transcript.
When did Novus Therapeutics' stock split?: Novus Therapeutics's stock reverse split on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.
What other stocks do shareholders of Novus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Novavax (NVAX), Geron (GERN), Inovio Pharmaceuticals (INO), Verastem (VSTM) and vTv Therapeutics (VTVT).

This page (NASDAQ:NVUS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Novus Therapeutics (NVUS) Stock Price, News & Analysis

About Novus Therapeutics Stock (NASDAQ:NVUS)

NVUS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NVUS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info